Health, Medical & Pharma News - Updated Daily page 34

Mental Health Care Use, Mortality Rates Increased With Prolonged Grief

Relatives bereaved by natural death with high and sustained grief symptoms have increased mental health care use and mortality for up to 10 years after the loss

Many Young Vapers Make Potentially Dangerous Tweaks To Their Devices

FRIDAY, July 25, 2025 Most teens and young adults who vape tinker with their devices, often in potentially dangerous ways, a new study says. More than 4 out of

Heavy Grief Nearly Doubles Bereaved's Risk Of Early Death

FRIDAY, July 25, 2025 People intensely grieving a loved one are nearly twice as likely to die within a decade of their loss, a new study says. Those whose grief

African Psychedelic Might Help Combat Vets Recover From Traumatic Brain Injury

FRIDAY, July 25, 2025 Veterans who receive traumatic brain injuries in combat often experience crippling post-traumatic stress disorder, anxiety and depression,

Vitamin D Might Offer Protection Against COVID-19

FRIDAY, July 25, 2025 Low vitamin D levels might increase a person s odds of a severe bout with COVID-19, a new study says. People with a vitamin D deficiency a

Number Of Family Caregivers Has Skyrocketed in The U.S.

FRIDAY, July 25, 2025 The number of Americans caring for an older or disabled family member has risen dramatically during the past 10 years, according to a new

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

PARIS, France July 22, 2025 10 05 PM CEST Abivax SA (Euronext Paris FR0012333284 ABVX Nasdaq ABVX) ( Abivax or the Company ), a clinical-stage biotechnology com

Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea

CAMBRIDGE, Mass., July 23, 2025 Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that address the

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

Revolution Medicines, Inc. (Nasdaq RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today ann

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Verastem Oncology (Nasdaq VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS MAPK pathway-driven cancers, today annou

Pharmaceutical News and Articles